Whilst Jeremy Hunt says he has no leeway to cut UK taxes at present, we at o2h Ventures are seeing a surge in investment opportunities from early-stage UK biotech. It feels like we are at the beginning of the next investment cycle and given the overall investment appetite and our growing presence; we have a large number of investment options coupled with more realistic valuations.
We are thrilled to announce the launch of our latest investment opportunity, the Knowledge-intensive EIS Fund VI which is open for investment till 31st October 2023, and we believe this is the perfect time for our valued investors to be part of an exhilarating biotech portfolio. We aim to fully deploy our funds within a 12-month time frame in 5-10 biotech companies most of which will be de-risked follow-on investment in the most exciting companies in the existing portfolio. Check out our existing portfolio here.
o2h Ventures Awards and Recognition
Celebrating Hat-trick of Awards! – We are thrilled to announce that we have been selected as finalists in three prestigious awards this year in all three different categories.
UKBAA Awards: Finalist for the Best Regional Manager category.
EISA Awards: Finalist for the prestigious EIS Impact Award 2023.
Growth Investor Awards: Finalists for the Best EIS Investment Manager – Specialist category (results coming soon)
Read this article on Powering regional growth – the Cambridge cluster in collaboration with Intelligent Partnership
If you are interested in gaining valuable insights into biotech investing, tax-efficient investment strategies, and the future of the industry, do not miss our CEO, Sunil Shah’s latest article HERE.
Furthermore, if you wish to delve deep into the world of biotech investing, tune into this episode of the EIS Navigator Podcast – Biotech Update and Investing. Listen to the podcast here – click here.
Deals executed:
Pencil Biosciences (Alderly Park, Manchester): specializing in gene editing and modulation technology, successfully secured seed funding of £5.6M raise, o2h Ventures co-invested with Octopus Investments and Northen Gritstone. o2h Ventures had also earlier invested into the Pre-Seed round. To read more about it, click here.
Some key portfolio highlights:
- Kuano, a pioneering drug discovery company, has successfully concluded its seed funding round, securing a substantial £1.8 million. Kuano distinguishes itself through its innovative fusion of quantum mechanics and artificial intelligence in the pursuit of next-generation medicines. o2h Ventures had also earlier invested into the PreSeed round and provided Board level support.
- Cybin set to acquire Small Pharma U.K.-based biotechnology company focused on short-duration psychedelic therapies for mental health conditions.
- Heartfelt Technologies won the prestigious Santander X Global Challenge | The AI Revolution, organised by Santander, Microsoft and Oxentia Foundation. Heartfelt Technologies is dedicated to supporting patients, their families, carers and doctors, to reduce hospital readmission rates from heart failure decompensation.
Meet us at Cambridge – Ready Steady Grow, a knowledge share and networking event managed by the EISA, that will provide attendees updates on funding options and the latest developments in the Enterprise Investment Scheme (EIS) and SEIS industry. Register here.
Check out this Hardman report on knowledge-intensive EIS fund
Take a look at the comprehensive Tax Enhanced Research published by Hardman & Co about the o2h Human Health EIS Knowledge-Intensive Fund. With a vast team of investment professionals and market analysts, Hardman & Co provides unparalleled insights into tax-enhanced products. Download from here.
